RecruitingPhase 2NCT06057675

Tranexamic Acid in Nasal Mohs Reconstruction

Subcutaneous Tranexamic Acid in Nasal Mohs Local Flap Reconstruction: Perioperative Bleeding, Edema, and Ecchymosis


Sponsor

Vanderbilt University Medical Center

Enrollment

100 participants

Start Date

Mar 19, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Adults at least 18 years of age undergoing local flap reconstruction (bilobe flap, note flap dorsal nasal flap, advancement flap) of a nasal defect following Mohs micrographic surgery. Reconstructive procedures will be performed by Drs. Yang or Patel in the division of Facial Plastic Surgery in the Department of Otolaryngology, Head and Neck Surgery at Vanderbilt University Medical Center.
  • No other facial plastic procedure or sinus surgery performed simultaneously.

Exclusion Criteria12

  • Known allergy to TXA
  • Intracranial bleeding
  • Known defective color vision
  • History of venous or arterial thromboembolism
  • History of coagulation disorder
  • Active thromboembolic disease
  • Severe renal impairment (diagnosis of chronic kidney disease)
  • History of acute myocardial infarction
  • History of stroke
  • History of seizure
  • History of liver failure
  • Preoperative lab results indicating thrombocytopenia (platelets <150,000), increased bleeding risk (PT over 45, INR over 1.2).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTreatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine)

Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine) and tranexamic acid (1g/10mL), mixed in a 9:1 volume ratio.

DRUGControl (1% lidocaine with 1:100,000 epinephrine)

Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine)


Locations(1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06057675


Related Trials